Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symphony-1: Tazemetostat + R2 in Relapsed/Refractory Follicular Lymphoma
NCT04224493Phase 3Active, not recruiting
- Sponsor
- Epizyme, Inc.
- Start
- Jun 2020
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) comparing Tazemetostat + R2 arm with Placebo + R2 Arm (2 arms). Primary endpoints: Recommended Phase 3 Dose at 28 days and Progression-Free Survival up to 72 months. Started Jun 2020; status: active, not recruiting.
02
Drugs
tazemetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04224493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04224493.